1. Inicio
  2. Publicaciones
  3. Cytomegalovirus Reactivation Is Associated With Lower Rates of Hepatocellular Carcinoma Recurrence After Liver Transplantation

Cytomegalovirus Reactivation Is Associated With Lower Rates of Hepatocellular Carcinoma Recurrence After Liver Transplantation

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Romero, M
  • Zamora-Olaya, J
  • Gómez-Bravo, MA
  • Fuentes-Valenzuela, E
  • Dopazo, C
  • Bilbao, N
  • Gonzalez, A
  • Sanchez-Martinez, A
  • Pascual, S
  • Rivera-Esteban, J
  • Herrero, JI
  • Lorente, S
  • Cuadrado-Lavin, A
  • Nogueras, F
  • González-Grande, R
  • Rodriguez-Perálvarez, M

Grupos

Abstract

In patients with hepatocellular carcinoma (HCC), undergoing liver transplantation (LT), cytomegalovirus reactivation (CMVr) may modulate the immune system to prevent tumor recurrence. In this multicenter retrospective study (2010-2015) involving 15 institutions, we assessed the effect of early CMVr in tumor recurrence rates among 771-LT HCC patients with tacrolimus-based immunosuppression (88% men, mean age 58 years). CMV prophylaxis was implemented for 19.7% of patients, while the rest were managed with preemptive therapy. The Milan criteria were met by 88% of patients. Microvascular invasion was present in 12.7% of explanted livers. The serum AFP level before transplantation was 5.1 (3-15) ng/mL. After a median follow-up of 7.4 years, 101 patients (13%) experienced HCC recurrence. CMVr occurred in 235 patients (30.5%) at a median of 41.5 days post-LT and 42 patients (5.6%) had CMV disease. Cumulative exposure to tacrolimus within the first 3 months after LT was similar among patients with and without CMVr. In a multivariate Cox regression analysis, factors associated with an increased rate of HCC recurrence included microvascular invasion [HR:2.82, CI95%:1.55-5.14; p 0.0001], donation after circulatory determination of death [HR:4.43,CI95%:1.52-12.9; p 0.006) and diameter of the main nodule at explant [HR:1.04, CI95%:1.02-1.06; p < 0.001]. Meanwhile CMVr [HR:0.46, CI95%:0.23-0.93, p 0.031] and MELD [HR:0.93, CI95%:0.87-0.99; p0.017] exhibited protective effects. In conclusion, early CMVr may protect against HCC recurrence. The underlying immune mechanisms warrant further investigation.

Copyright © 2025 Aguilera, Romero Moreno, Conde, Rubín, Carvalho-Gomes, Romero, Zamora-Olaya, Gómez-Bravo, Fuentes-Valenzuela, Dopazo, Bilbao, González, Sánchez-Martínez, Pascual, Rivera-Esteban, Herrero, Lorente, Cuadrado-Lavín, Nogueras, Martínez-Arenas, González-Grande, Berenguer and Rodriguez-Perálvarez.

Datos de la publicación

ISSN/ISSNe:
0934-0874, 1432-2277

TRANSPLANT INTERNATIONAL  FRONTIERS MEDIA SA

Tipo:
Article
Páginas:
14553-14553
PubMed:
40557335
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
1,005 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 1

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • liver transplantation; cytomegalovirus; survival; hepatocellular carcinoma; donation after circulatory determination of death; Immunosupression

Proyectos y Estudios Clínicos

IMPACTO DE LA RESPUESTA INMUNE CELULAR ESPECÍFICA CONTRA CITOMEGALOVIRUS (CMV) TRAS EL TRASPLANTE HEPÁTICO EN LA AGRESIVIDAD DE LA HEPATITIS C RECURRENTE.

Investigador Principal: VICTORIA AGUILERA SANCHO-TELLO

PI13/01770 . INSTITUTO DE SALUD CARLOS III . 2014

El viroma como biomacador no invasivo del estado de inmunocompetencia y riesgo de infecciones en el trasplante hepático.

Investigador Principal: VICTORIA AGUILERA SANCHO-TELLO

PI18/01759 . INSTITUTO DE SALUD CARLOS III; FUNDACION ESPAÑOLA PARA EL ESTUDIO DEL HIGADO . 2019

Contrato PFIS 2020. Laura Martínez Arenas

Investigador Principal: MARINA BERENGUER HAYM

FI20/00033 . INSTITUTO DE SALUD CARLOS III . 2021

El impacto de la esteatohepatitis no alcohólica (EHNA) en el trasplante hepático (TH) con perspectiva geográfica

Investigador Principal: MARINA BERENGUER HAYM

AICO/2021/035 . CONSELLERIA DE INNOVACIÓN, UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL . 2021

Contrato M-AES 2022. LAURA MARTÍNEZ

Investigador Principal: LAURA MARTÍNEZ ARENAS

MV22/00053 . INSTITUTO DE SALUD CARLOS III . 2023

EducaTH: Condicionantes genéticos y ambientales del síndrome metabólico posttrasplante hepático. Programa de intervención personalizada.

Investigador Principal: MARINA BERENGUER HAYM

PI23/00088 . INSTITUTO DE SALUD CARLOS III . 2024

EducaTH: Condicionantes genéticos y ambientales del síndrome metabólico posttrasplante hepático. Programa de intervención personalizada.

Investigador Principal: MARINA BERENGUER HAYM

CIPROM/2023/16 . CONSELLERIA DE INNOVACIÓN, UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL . 2024

Contrato de intensificación 2024. Marina Berenguer Haym.

Investigador Principal: MARINA BERENGUER HAYM

INT24/00021 . INSTITUTO DE SALUD CARLOS III . 2025

Cita

Compartir